Lyell Immunopharma says additional clinical data and end-of-phase 1 FDA meeting expected in 2027

LYEL•2026-09-10

Manufacturing transfer and trial timeline update

Lyell Immunopharma, Inc. said it has completed the manufacturing transfer for LYL273 and provided an updated timeline on its phase 1/2 trial in metastatic colorectal cancer.

The company said additional clinical data and an end-of-phase 1 FDA meeting are expected in 2027.

Lyell Immunopharma says additional clinical data and end-of-phase 1 FDA meeting expected in 2027

Manufacturing transfer and trial timeline update

Related News

Actinium Pharmaceuticals CSO Kamal Adeela files initial beneficial ownership statement

iSpecimen gets Nasdaq extension to meet $2.5 million stockholders’ equity rule by Nov. 25

Kestra Medical Technologies holds annual shareholder meeting

Axon CEO Patrick W. Smith sells 10,000 shares worth $5.08 million

Safe Bulkers elects Adamopoulos, Holth, Hajioannou as Class III directors